Found 38 results in Expert Content

Learn how the right process, clonal HEK293 cell line, and range of off-the-shelf plasmids, along with qualified analytical methods supports a robust supply chain for the development and manufacture of AAV vectors, and the reduction of timelines to clinical evaluation.

In this webinar, experts will discuss the evolution of protocols associated with induced pluripotent stem cell generation and differentiation.

Summary: One significant challenge in the manufacturing of cell and gene therapies is the production of high quality plasmid DNA (pDNA). pDNA is a critical raw material for advanced therapeutics including mRNA and viral vector-based cell and gene therapies and vaccines.

Human induced pluripotent stem cells (iPSCs) enable availability of next-generation cell therapies for broader patient population at a faster turnaround time for a variety of disease areas. Two Catalent Cell & Gene Therapy experts discuss the use of iPSCs as starting materials for cellular therapies, including the concept behind a universal platform for iPSC-based therapies.

Drug developers face mounting challenges linked to rapid increases in demand for the complex modalities while also accounting for the need to drive process efficiencies at scale. Working with the right partner, that offers integrated services, can help ease the increasingly common problems with scale, access to high-demand raw material, viral vector production, and quality requirements.

Summary: Catalent Cell & Gene Therapy experts spoke with American Pharmaceutical Review to discuss how cell and gene therapies are changing the healthcare landscape and what needs to be done to bring these advanced therapies to patients.

Join us as our panel of experts discuss key manufacturing challenges for early and late-stage gene-enabled cell therapy programs, as well as how to overcome them through effective partnerships.

Summary: Join us as our panel of experts discuss key manufacturing challenges for early and late-stage gene-enabled cell therapy programs, as well as how to overcome them through effective partnerships.

Summary: In this on-demand webinar, hear our product development expert discuss Catalent’s UpTempo Virtuoso AAV platform process, a scalable, CGMP-ready platform process that can significantly reduce the time from gene to clinic.

Summary: A scalable, CGMP-ready process for viral vector manufacturing that reduces the current 18-20-month development timeline for drug product in half.